sulbutiamine and Asthenia

In this article, we try to present the available data regarding the pharmacokinetics and pharmacodynamics of sulbutiamine (Enerion), the mechanisms of its anti-asthenic action. Then we analyze and summarize the available evidence base considering the efficacy and safety of Enerion for the treatment of asthenic syndromes. Then we compare Enerion with some other drugs. The results of our review indicate the high efficacy and safety of sulbutiamine in the treatment of asthenia. Our results also show that Enerion has some clinically relevant advantages over all alternatives we reviewed there.. В данной статье мы постарались представить читателю в краткой и сжатой форме данные о фармакокинетике и фармакодинамике препарата сульбутиамин (Энерион), о механизмах его антиастенического действия, проанализировать и обобщить имеющуюся доказательную базу по эффективности и безопасности применения Энериона для лечения астенических состояний, провести сравнение его с некоторыми альтернативными препаратами. Результаты нашего обзора свидетельствуют о высокой эффективности и безопасности Энериона при лечении астении, а также о наличии у него клинически значимых преимуществ перед всеми рассмотренными альтернативами.

Topics: Asthenia; Humans; Syndrome; Thiamine

Asthenia is a key symptom of posttraumatic disorders (postcommotion syndrom). The dynamics of the symptom developing after mild cranio-cerebral trauma was studied during the treatment of 36 patients with enerion (20 patients) and piracetam (16 patients - control group). The authors present the results of the complex study, which includes neuropsychological tests and scales. It was shown that enerion was more effective as compared with paracetam.

Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Brain Injuries; Female; Humans; Male; Middle Aged; Thiamine

Asthenic symptoms such as weakness accompany illness. This study investigates whether the centrally acting cholinergic agent, vitamin B analogue (sulbutiamine), is effective and acceptable in relieving these symptoms in infectious disease when combined with specific anti-infective treatment.. In a prospective uncontrolled, non-randomised, commercial, observational study, 1772 patients with an infectious disease and asthenic symptoms, drawn from the practice of 350 randomly selected physicians throughout India, received vitamin B analogue (sulbutiamine) in addition to specific anti-infective treatment for 15 days. The primary outcome variable was complete resolution of asthenic symptoms with treatment.. The number (%, 95% confidence interval) of patients with complete resolution of all asthenic symptoms was 916 (51.7, 49.4-54). In the remaining patients, severe asthenia was reduced but persisted in 11 (0.6, 0-26); and moderate asthenia in 94 (5.3, 0-17.6). The response was greater in patients with acute infection and symptoms more related to cerebral function. Side effects occurred in 10 (0.6%), patients and well being improved significantly.. Vitamin B analogue (sulbutiamine) may be a useful adjunct to specific anti-infective treatment.

Topics: Adult; Asthenia; Confidence Intervals; Female; Humans; India; Male; Prospective Studies; Severity of Illness Index; Thiamine; Treatment Outcome

Topics: Adolescent; Adult; Aged; Antidepressive Agents; Asthenia; Cardiovascular Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Neurasthenia; Psychotropic Drugs; Thiamine